Atypical depression: Retrospective self-reporting of treatment effectiveness

Acta Psychiatrica Scandinavica

Volumn 120, Issue 3, 2009, Pages 213-221

  Parker, G ^a,b   Crawford, J ^c  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b BLACK DOG INSTITUTE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Depressive disorder; Drug therapy; Psychotherapy; Therapeutics

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HERBACEOUS AGENT; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ARTICLE; ATYPICAL DEPRESSION; CLINICAL FEATURE; COGNITIVE THERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONLINE SYSTEM; PRIORITY JOURNAL; PSYCHOTHERAPY; RETROSPECTIVE STUDY; SELF REPORT; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHARACTER; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TEMPERAMENT; YOUNG ADULT;

EID: 68249092217     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2009.01376.x     Document Type: Article

References (28)

1. Asnis GM, Mcginn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry 1995 152 : 31 36.
2. Angst J, Gamma A, Sellaro R, Zhang H, Merikangas K. Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord 2002 72 : 125 138.
3. Stewart JW, Mcgrath PJ, Rabkin JG, Quitkin FM. Atypical depression: a valid clinical entity? Clin North Am 1993 16 : 479 495.
4. West ED, Dally PJ. Effect of iproniazid in depressive syndromes. Br Med J 1959 1 : 1491 1494.
5. Sargant W. The treatment of anxiety states and atypical depressions by the monoamine oxidase inhibitor drugs. J. Neuropsychiatry 1962 3 (suppl. 1 96 103.
6. Pollitt JD. Suggestions for a physiological classification of depression. Br J Psychiatry 1965 111 : 489 495.
7. Pare CM. Monoamine oxidase inhibitors in resistant depression. Int Pharmacopsychiatry 1979 14 : 101 109.
8. Klein DF, Davis JM. Diagnosis and drug treatment of psychiatric disorders. Baltimore, MD : Williams and Wilkins, 1969.
9. Quitkin FM, Harrison W, Stewart JW et al. Response to phenelzine and imipramine in placebo nonresponders with atypical depression: a new application of the crossover design. Arch Gen Psychiatry 1991 48 : 319 323.
10. Mcgrath PJ, Stewart JW, Nunes EV et al. A double-blind cross-over trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993 150 : 118 123.
11. Liebowitz MR, Quitkin FM, Stewart JW et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988 45 : 129 137.
12. Quitkin FM, Mcgrath PJ, Stewart JW et al. Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Arch Gen Psychiatry 1990 47 : 935 941.
13. Henkel V, Mergl R, Allgaier A-K, Kohnen R, Moller H-J, Hergerl U. Treatment of depression with atypical features: A meta-analytic approach. Psychiatry Res 2006 141 : 89 101.
14. Quitkin FM, Mcgrath PJ, Stewart JW et al. Phenelzine and imipramine in mood reactive depressives. Arch Gen Psychiatry 1989 46 : 787 793.
15. Davidson JR, Giller EL, Zisook S, Overall JE. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry 1988 45 : 120 127.
16. Stewart JW. Treating depression with atypical features. J Clin Psychiatry 2007 68 (suppl. 3 25 29.
17. Roose SP, Miyake M, Devanand D et al. An open trial of venlafaxine for the treatment of late-life atypical depression. Int J Geriatric Psych 2004 19 : 989 994. (Pubitemid 39378294)
18. Mcgrath PJ, Stewart JW, Harrison WM, Wager S, Nunes EN, Quitkin FM. A placebo-controlled trial of l-deprenyl in atypical depression. Psychopharmacol Bull 1989 25 : 63 67.
19. Rye DB, Dihenia B, Bliwise DL. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Dep Anxiety 1998 7 : 92 95.
20. Jarret RB, Schaffer M, Mcintire D, Witt-Browder A, Kraft D, Risser RC. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999 56 : 431 437.
21. Stewart JW, Garfinkel R, Nunes EV, Donovan S, Klein DF. Atypical features and treatment response in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Clin Psycholopharm 1998 18 : 429 434.
22. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008 5 : e45.
23. Parker G, Manicavasagar V, Crawford J, Tully L, Gladstone G. Assessing personality traits associated with depression: the utility of a tiered model. Psychol Med 2006 36 : 1131 1139.
24. SPSS INC. spss for Windows Release 15.0.0 (6 Sep 2006). Chicago, IL, USA.
25. Parker G, Roy K, Mitchell P, Wilhelm K, Malhi G, Hadzi-Pavlovic D. Atypical depression: a reappraisal. Am J Psychiatry 2002 159 : 1470 1479.
26. Parker GB, Crawford J. A spectrum model for depressive conditions: extrapolation of the atypical depression prototype. J Affect Disord 2007 103 : 155 163.
27. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand 2008 118 : 434 442.
28. Parker G, Fletcher K. Treating depression with evidence-based psychotherapies: a critique of the evidence. Acta Psychiatr Scand 2007 115 : 352 359.